Anagrelide
Back to searchMolecule Structure
Scientific Name
Anagrelide
Description of the Drug
Anagrelide is a platelet-reducing agent used to treat thrombocythemia, and its related complications, secondary to myeloproliferative neoplasms.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00261
http://www.drugbank.ca/drugs/DB00261
Brand Name(s)
Not Available
Company Owner(s)
Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa, Takeda Pharmaceuticals Usa Inc, Watson Laboratories, Chartwell Rx Sciences Llc, Roxane Laboratories Inc, Mylan Pharmaceuticals Inc, Barr Laboratories Inc, Impax Laboratories Inc, Torrent Pharmaceuticals Ltd
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Phosphodiesterase 3 | PROTEIN FAMILY | INHIBITOR | CHEMBL2094125 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL9411 | ||
PharmGKB | PA164742986 | ||
Human Metabolome Database | HMDB0014406 | ||
DrugBank | DB00261 | ||
PubChem: Thomson Pharma | 14798804 | 14774505 | |
PubChem | 135409400 | ||
LINCS | LSM-3380 | ||
Nikkaji | J18.596E | ||
PDBe | J33 | ||
BindingDB | 50000334 | ||
DrugCentral | 209 | ||
ChemicalBook | CB8246866 | ||
Guide to Pharmacology | 7114 | ||
rxnorm | AGRYLIN | ANAGRELIDE HYDROCHLORIDE | ANAGRELIDE |
ChEBI | 142290 | ||
ZINC | ZINC000003871541 |